US 07,846,441 B1
Treatment with anti-ErbB2 antibodiesGeneral
US 07,846,441 B1
Treatment with anti-ErbB2 antibodies
Tech Center:
1600 Biotechnology and Organic Chemistry
Examiner:
Alana M. Harris
Art Unit:
1643 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology
Inventors:
Susan D. Hellmann
Assignee:
Priority:
12/12/97
Filed:
12/10/98
Granted:
12/07/10
Expiration:
01/09/23
Abstract
The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.